Cancer treatment

Also known as: Chemotherapy / Chemotherapies / Chemotherapy NOS

DrugDrug NameDrug Description
DB00437AllopurinolA xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. Allopurinol is considered a standard treatment of hyperuricemia associated with gout. In August 2017, an oral combination agent Duzallo was approved by FDA as a dual-mechanism treatment of hyperuricemia in patients with uncontrolled gout. Duzallo contains allopurinol and [Lesinurad], a recently FDA-approved URAT1 inhibitor indicated for the treatment of hyperuricemia associated with gout.
DB00470DronabinolDronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are found throughout the body [A32830]. While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms like Dronabinol or [DB00486]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. From a pharmacological perspective, Cannabis' diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body [A32584]. The endocannabinoid system is widely distributed throughout the central and peripheral nervous system (via the Cannabinoid Receptors CB1 and CB2) and plays a role in many physiological processes such as inflammation, cardiovascular function, learning, pain, memory, stress and emotional regulation, and the sleep/wake cycle among many others [A32824]. CB1 receptors are found in both the central and peripheral nervous system, and are most abundant in the hippocampus and amygdala, which are the areas of the brain responsible for short-term memory storage and emotional regulation. CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [A32676].
DB00016ErythropoietinErythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells. It works by promoting the division and differentiation of committed erythroid progenitors in the bone marrow [FDA Label]. Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein produced in cell culture using recombinant DNA technology and is used for the treatment of patients with anemia associated with various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin and has the same biological activity as the endogenous erythropoietin. Epoetin alfa biosimilar, such as Retacrit (epoetin alfa-epbx or epoetin zeta), has been formulated to allow more access to treatment options for patients in the market [L2784]. The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504]. Epoetin alfa formulations can be administered intravenously or subcutaneously.
DB00070Hyaluronidase (ovine)Highly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.
DB09517Sodium ferric gluconate complexSodium ferric gluconate complex is an iron replacement product for treatment of iron deficiency anemia. The stable macromolecular complex is negatively charged at alkaline pH with an apparent molecular weight of 289,000 – 440,000 daltons on gel chromatography. It is composed of iron (III) oxide hydrate directly bonded to sucrose with a chelating gluconate function in a molar ratio of two iron molecules to one gluconate. It is used in adult and in pediatric patients over the age of 6 years with chronic kidney disease (CKD) receiving hemodialysis and receiving supplemental epoetin therapy.
DB00364SucralfateA basic aluminum complex of sulfated sucrose. [PubChem]
DB13946Testosterone undecanoateTestosterone undecanoate is an esterified form of testosterone which is attached to a long fatty acid chain. The lack of a methylated site on the carbon 17 eliminates the adverse effects on the liver found in other testosterone analogs.[L1164] It is currently getting further developed to be an alternative to testosterone enanthate or testosterone cypionate by Paddock labs, and this new injectable has an FDA status of tentative approval. The original approval by the FDA of a product from testosterone undecanoate was done in 1953.
DrugDrug NameTargetType
DB00437AllopurinolXanthine dehydrogenase/oxidasetarget
DB00437AllopurinolSolute carrier family 22 member 8transporter
DB00437AllopurinolSolute carrier family 22 member 7transporter
DB00437AllopurinolAldehyde oxidaseenzyme
DB00437AllopurinolXanthine dehydrogenase/oxidaseenzyme
DB00470DronabinolCannabinoid receptor 1target
DB00470DronabinolCytochrome P450 3A4enzyme
DB00470DronabinolCytochrome P450 2C9enzyme
DB00470DronabinolCannabinoid receptor 2target
DB00470DronabinolMultidrug resistance protein 1transporter
DB00470DronabinolATP-binding cassette sub-family G member 2transporter
DB00470DronabinolCytochrome P450 2C19enzyme
DB00470DronabinolProstaglandin G/H synthase 1enzyme
DB00470DronabinolCytochrome P450 1A1enzyme
DB00470DronabinolCytochrome P450 2A6enzyme
DB00016ErythropoietinErythropoietin receptortarget
DB00070Hyaluronidase (ovine)Transforming growth factor beta-1target
DB00070Hyaluronidase (ovine)Serum albumincarrier
DB00070Hyaluronidase (ovine)Hyaluronantarget
DB09517Sodium ferric gluconate complexFerritin light chaintarget
DB09517Sodium ferric gluconate complexHemoglobin subunit alphatarget
DB09517Sodium ferric gluconate complexHemoglobin subunit betatarget
DB00364SucralfateSerum albumincarrier
DB00364SucralfateFibrinogen alpha chaintarget
DB00364SucralfateFibrinogen beta chaintarget
DB00364SucralfateFibrinogen gamma chaintarget
DB00364SucralfatePro-epidermal growth factortarget
DB00364SucralfateFibroblast growth factor 2target
DB13946Testosterone undecanoateAndrogen receptortarget
DB13946Testosterone undecanoateCytochrome P450 3A4enzyme
DB13946Testosterone undecanoateCytochrome P450 19A1enzyme
DB13946Testosterone undecanoateAmine oxidase [flavin-containing] Aenzyme
DB13946Testosterone undecanoateCholesterol side-chain cleavage enzyme, mitochondrialenzyme
DB13946Testosterone undecanoateSerum albumincarrier
DB13946Testosterone undecanoateSex hormone-binding globulincarrier
DB13946Testosterone undecanoateCytochrome P450 3A5enzyme
DB13946Testosterone undecanoateCytochrome P450 3A7enzyme
DB13946Testosterone undecanoateSolute carrier organic anion transporter family member 1A2transporter
DB13946Testosterone undecanoateSolute carrier family 22 member 8transporter
DB13946Testosterone undecanoateSolute carrier family 22 member 7transporter
DB13946Testosterone undecanoateMultidrug resistance protein 1transporter
DB13946Testosterone undecanoateSodium/bile acid cotransportertransporter
DB13946Testosterone undecanoateSolute carrier family 22 member 3transporter
DB13946Testosterone undecanoateSolute carrier family 22 member 4transporter
DB13946Testosterone undecanoateATP-binding cassette sub-family G member 2transporter
DB13946Testosterone undecanoateCytochrome P450 1A1enzyme
DB13946Testosterone undecanoateCytochrome P450 1B1enzyme
DB13946Testosterone undecanoateCytochrome P450 2A13enzyme
DB13946Testosterone undecanoateCytochrome P450 2B6enzyme
DB13946Testosterone undecanoateCytochrome P450 2C19enzyme
DB13946Testosterone undecanoateCytochrome P450 2C8enzyme
DB13946Testosterone undecanoateCytochrome P450 2C9enzyme
DB13946Testosterone undecanoateCytochrome P450 3A43enzyme
DB13946Testosterone undecanoateEstrogen receptor alphatarget
DB13946Testosterone undecanoateMineralocorticoid receptortarget
DB13946Testosterone undecanoate3-oxo-5-alpha-steroid 4-dehydrogenaseenzyme
DrugDrug NamePhaseStatusCount
DB01101Capecitabine1 / 2Unknown Status1
DB06772Cabazitaxel2Not Yet Recruiting1
DB01248Docetaxel2Not Yet Recruiting1
DB03147Flavin adenine dinucleotide2Unknown Status1
DB01073Fludarabine2Unknown Status1
DB00282Pamidronic acid2Terminated1
DB00531Cyclophosphamide2 / 3Not Yet Recruiting1
DB01248Docetaxel2 / 3Not Yet Recruiting1
DB00445Epirubicin2 / 3Not Yet Recruiting1
DB00014Goserelin2 / 3Not Yet Recruiting1
DB01006Letrozole2 / 3Not Yet Recruiting1
DB00675Tamoxifen2 / 3Not Yet Recruiting1
DB01248Docetaxel3Unknown Status1
DB00445Epirubicin3Unknown Status1
DB11242Gelatin3Unknown Status1
DB00159Icosapent3Unknown Status1
DB00012Darbepoetin alfa4Completed1
DB00650LeucovorinNot AvailableCompleted1